# Study of Anlotinib Hydrochloride and Toripalimab in Subjects With Unresectable or Metastatic Undifferentiated Pleomorphic Sarcoma

> **NCT03946943** · PHASE2 · UNKNOWN · sponsor: **Di Wu** · enrollment: 25 (estimated)

## Conditions studied

- Soft Tissue Sarcomas
- Undifferentiated Pleomorphic Sarcoma

## Interventions

- **DRUG:** Anlotinib
- **DRUG:** Toripalimab
- **PROCEDURE:** Blood Draw
- **PROCEDURE:** Tumor Specimen Collection

## Key facts

- **NCT ID:** NCT03946943
- **Lead sponsor:** Di Wu
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-07-19
- **Primary completion:** 2022-07-19
- **Final completion:** 2023-07-19
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2019-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03946943

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03946943, "Study of Anlotinib Hydrochloride and Toripalimab in Subjects With Unresectable or Metastatic Undifferentiated Pleomorphic Sarcoma". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03946943. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*